

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**EVERGRANDE HEALTH
INDUSTRY GROUP**

EVERGRANDE HEALTH INDUSTRY GROUP LIMITED

恒大健康產業集團有限公司

(a company incorporated in Hong Kong with limited liability)

(Stock code: 708)

**BUSINESS UPDATE
COMMENCEMENT OF STRATEGIC COLLABORATION WITH
BRIGHAM AND WOMEN'S HOSPITAL**

The Company is pleased to announce that, on 24 September 2015, Evergrande Health Industry Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) entered into a memorandum of understanding (the “**MOU**”) with Brigham and Women’s Hospital. Brigham and Women’s Hospital will serve as the strategic partner to the Company as they endeavor to advance the healthcare delivery system in China.

Brigham and Women’s Hospital will provide the Group with strategic guidance on healthcare-related projects. Specifically, Brigham and Women’s Hospital will advise the Group in the areas of healthcare administration, training, hospital design and clinical programs.

Brigham and Women’s Hospital is a nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. The medical preeminence of Brigham and Women’s Hospital dates back to 1832, and today, through investigation and discovery conducted at its Brigham Research Institute (BRI), Brigham and Women’s Hospital is an international leader in basic, clinical and translational research on human diseases. For the last 25 years, Brigham and Women’s Hospital ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals.

GENERAL

As the MOU is not legally binding, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

There can be no assurance that any forward-looking statements regarding the business development of the Group set out in this announcement or any of the matters set out therein are attainable, will actually occur or will be realised or are complete or accurate. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By Order of the Board
Evergrande Health Industry Group Limited
Fong Kar Chun, Jimmy
Company Secretary

Hong Kong, 24 September 2015

As at the date of this announcement, the executive directors of the Company are Ms. Tan Chaohui, Mr. Tong Ming, Mr. Han Xiaoran; and the independent non-executive directors of the Company are Mr. Chau Shing Yim, David, Mr. Guo Jianwen and Mr. Xie Wu.